Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.36 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.36 |
| ▸ | EPHA8 | P29322 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.36 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.36 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197931 | 0.83 | EGFR (0.40) | EGFRSRC | |
| SCHEMBL197930 | 0.81 | PDGFRB (0.33) | PDGFRBPDGFRAPGK1 | |
| SCHEMBL5224388 | 0.79 | EHMT2 (0.33) | PDGFRBPDGFRA | |
| SCHEMBL199314 | 0.79 | EHMT2 (0.60) | — | |
| SCHEMBL199299 | 0.78 | EHMT2 (0.51) | EGFRSRC | |
| SCHEMBL198154 | 0.76 | KMT5A (0.43) | EGFRNCF1 | |
| SCHEMBL199128 | 0.76 | AXL (0.52) | KDM4EEGFRSRCGAKEPHB6 | |
| SCHEMBL2747062 | 0.74 | ALDH1A1 (0.39) | KDM4EALDH1A1SMN1; SMN2GAK | |
| SCHEMBL590041 | 0.74 | LMNA (0.43) | PDGFRBPDGFRAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL20918178 | 0.74 | LOX (0.36) | PDGFRBPDGFRAKDM4EEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019078968-A2 | CYCLIC COMPOUNDS AS IMMUNOMODULATING AGENTS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-04-25 | — | — | WO | claimed |
| EP-1827434-B1 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | claimed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | claimed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | claimed |
| EP-1854787-B1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | claimed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | claimed |
| US-7626030-B2 | Compounds and methods of use | AMGEN INC. (US) | 2009-12-01 | — | — | US | claimed |
| JP-2007518823-A | — | — | 2007-07-12 | — | — | JP | claimed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | claimed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | claimed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | claimed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | claimed |
| EP-1711495-A2 | QUINOLINE, QUINAZOLINE, PYRIDINE AND PYRIMIDINE COUNDS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2006-10-18 | — | — | EP | claimed |
| WO-2006060318-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | AMGEN INC. | 2005-11-03 | — | — | US | claimed |
| WO-2005073224-A2 | QUINOLINE QUINAZOLINE PYRIDINE AND PYRIMIDINE COUNDS AND THEIR USE IN THE TREATMENT OF INFLAMMATION ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2005-08-11 | — | — | WO | claimed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | PDGFRB 28/4885PDGFRA 49/4885KDM4E 4131/4885 |
| US-20050245547-A1 | 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma | HGF, MET, HGFAC | PDGFRB 137/4885PDGFRA 48/4885KDM4E 3353/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | PDGFRB 33/4885PDGFRA 24/4885KDM4E 3048/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | PDGFRB 21/4885PDGFRA 19/4885KDM4E 3651/4885 |
| US-20060252777-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | PDGFRB 21/4885PDGFRA 26/4885KDM4E 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.